Grant: Proof of Principle Program - Phase I
University of British Columbia
$150,000.00
A Diagnostic Test for Granulosa Cell Tumours of the Ovary
EF 2009-10
Résumé
Ovarian cancer is comprised of several different subtypes. One of these subtypes in granulosa cell tumours of the ovary. These tumours can be very difficult to recognize because there is currently no definitive diagnostic test for this ovarian cancer subtype. Ultimately, diagnosis is based on the judgement of expert pathologists which can lead to inconsistencies and misdiagnosis of disease. The consequence of misdiagnosis is inappropriate treatment of patients. Our research group has recently identified a mutation in a gene called FOXL2 that is found in 97% of granulosa cell tumors. We are now working to develop an antibody that will specifically recognize only the mutant form of FOXL2. If successful, this antibody would lead to the definitive and unambiguous diagnosis of granulosa cell tumors of the ovary and could immediately be used by diagnostic pathology laboratories worldwide.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
194933
Name
Huntsman David G
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
A Diagnostic Test for Granulosa Cell Tumours of the Ovary
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Diagnostic Test; Foxl2; Granulosa Cell Tumours; Immunohistochemistry; Mutation-Specific Antibody; Ovarian Cancer
Abstract
Ovarian cancer is comprised of several different subtypes. One of these subtypes in granulosa cell tumours of the ovary. These tumours can be very difficult to recognize because there is currently no definitive diagnostic test for this ovarian cancer subtype. Ultimately, diagnosis is based on the judgement of expert pathologists which can lead to inconsistencies and misdiagnosis of disease. The consequence of misdiagnosis is inappropriate treatment of patients. Our research group has recently identified a mutation in a gene called FOXL2 that is found in 97% of granulosa cell tumors. We are now working to develop an antibody that will specifically recognize only the mutant form of FOXL2. If successful, this antibody would lead to the definitive and unambiguous diagnosis of granulosa cell tumors of the ovary and could immediately be used by diagnostic pathology laboratories worldwide.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Huntsman, David G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~
